Fragrance Allergen Disclosure Is Coming to Cosmetic Labels. The Question Is When, Not If.

5 days ago
3 min read

Tray of capped lab flasks filled with yellow, amber, and red liquids, neatly arranged on a metal bench in a science lab

If you've been waiting for the fragrance allergen rule under MoCRA to just quietly go away, it's time to let that hope go. It's not gone. It's just slow, and slow is not the same thing as safe to ignore.

What the Rule Actually Does

Under RIN 0910-AI90, the FDA has confirmed it intends to identify certain substances as fragrance allergens and require their disclosure directly on cosmetic product labels. This is a mandate written into the Modernization of Cosmetics Regulation Act of 2022, better known as MoCRA, and the agency has repeatedly reaffirmed it as a live, active priority even as the timeline has slipped more than once. The current target on the Unified Agenda points to a proposed rule, meaning the formal notice and comment rulemaking process hasn't even started yet, let alone concluded.

That timeline is well behind MoCRA's original statutory target. Earlier agenda cycles pointed to a proposed rule landing in 2025; the most recent projection pushes that to May 2026, and as of the most recent public tracking, nothing had yet appeared in the Federal Register. This rule has moved before. It will likely move again before it's final.

Why the EU Deadline Changes the Calculus

Here's the part that should actually get your attention: the EU isn't waiting on the US to catch up. Its expanded fragrance allergen disclosure requirement, covering 82 distinct allergens, carries its own binding compliance date that has already landed this year. Which means if you sell into both markets, or you're formulating with any eye toward international or wholesale distribution, the EU's clock is already running while the US rule is still sitting in proposed-rule limbo.

Brands that treat fragrance allergen disclosure as "an American regulatory issue for later" are missing the fact that the real deadline pressure is already here, just arriving from a different jurisdiction. Formulating to the EU's 82-allergen threshold now effectively future-proofs you against whatever the eventual US rule requires, since the domestic standard is widely expected to track the international one.

Why a Slow Timeline Is Not the Same as Low Urgency

It's tempting to read a slipping timeline as a sign this isn't worth acting on yet. That reading misses two important realities.

First, once a proposed rule does finally publish, the runway to comply is rarely as generous as companies hope. Reformulating a fragrance system, requalifying suppliers on allergen content, and reprinting labels across an entire SKU line takes real time, often more time than a standard comment-to-effective-date period allows for. Waiting for a final rule before starting any of that work is how brands end up unable to relabel fast enough once the deadline actually lands.

Second, allergen disclosure is exactly the kind of requirement that tends to arrive with real enforcement teeth once finalized. This isn't a soft suggestion about voluntary best practices. It's a labeling mandate that, once final, ties directly into MoCRA's enforceable misbranding and adulteration provisions. That's a very different risk profile than a general recommendation.

What Smart Brands Are Doing in the Meantime

Get your fragrance formulations mapped now. Know which known or suspected allergens exist in each product, at what concentration, and how that compares against the thresholds already used under the EU framework, generally 0.01 percent for rinse-off products and 0.001 percent for leave-on products.
Build allergen data collection directly into your supplier communication process. If your fragrance houses can already provide allergen content down to the component level, you're ahead of most of the market waiting to be told what's required.
Treat the EU's binding deadline as your practical planning horizon rather than the still-pending US rule. If your formulations are compliant with the tighter international standard, the eventual domestic rule is far less likely to catch you off guard.
Watch for the actual publication of the proposed rule. That's the moment the real work begins: understanding exact allergen lists, specific concentration thresholds, and label placement requirements as the FDA has written them, not as industry has anticipated them.
Don't let related MoCRA items fall off your radar either. Good Manufacturing Practice standards for cosmetic facilities and talc and asbestos testing methods are moving on similar, sometimes overlapping, timelines under the same statute.

The Bottom Line

MoCRA's delay isn't downtime. It's the window where brands either get organized or get caught flat-footed later. The companies that use this stretch to build real allergen documentation, informed by the EU's already-binding standard, will be the ones who barely notice when the US rule finally lands. Everyone else will be relabeling under genuine time pressure, with suppliers and print vendors who are just as backed up as they are.

If your current fragrance and labeling documentation wouldn't hold up under a disclosure requirement today, that's worth a real look before the rule decides for you instead.